Targeting Galectin-1 With Radiation and Immune Checkpoints in Head and Neck Cancer

Dhanya K. Nambiar, PhD
Published: Thursday, Apr 06, 2017



Dhanya K. Nambiar, PhD, Stanford University, discusses targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in head and neck cancer.

Galectin-1 is a carbohydrate binding protein that contributes to tumor-immune escape and disease progression. The tumors use galectin-1 as a barrier, which stops the immune response, says Nambiar.

Targeting galectin-1 and inhibiting it may allow for immune agents to infiltrate the tumor.
 


Dhanya K. Nambiar, PhD, Stanford University, discusses targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in head and neck cancer.

Galectin-1 is a carbohydrate binding protein that contributes to tumor-immune escape and disease progression. The tumors use galectin-1 as a barrier, which stops the immune response, says Nambiar.

Targeting galectin-1 and inhibiting it may allow for immune agents to infiltrate the tumor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x